nerolidol has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, S; Alam, MM; Ali, J; Ansari, MA; Haque, SE; Iqubal, A; Najmi, AK; Sharma, S; Syed, MA | 1 |
| Ali, J; Haque, MM; Haque, SE; Iqubal, A; Najmi, AK; Syed, MA | 1 |
2 other study(ies) available for nerolidol and Cirrhosis
| Article | Year |
|---|---|
Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice.
Topics: Animals; Apoptosis; Catalase; Connective Tissue Growth Factor; Cyclophosphamide; Fibrosis; Gene Expression Regulation; Glutathione; Heart; Inflammation; Male; Mice; Molecular Docking Simulation; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; RNA, Messenger; Sesquiterpenes; Transcription Factor RelA; Transforming Growth Factor beta1 | 2019 |
Nerolidol protects the liver against cyclophosphamide-induced hepatic inflammation, apoptosis, and fibrosis via modulation of Nrf2, NF-κB p65, and caspase-3 signaling molecules in Swiss albino mice.
Topics: Animals; Apoptosis; Caspase 3; Cyclophosphamide; Disease Models, Animal; Fibrosis; Inflammation; Liver; Liver Diseases; Male; Mice; NF-E2-Related Factor 2; Sesquiterpenes; Signal Transduction; Transcription Factor RelA | 2020 |